Literature DB >> 8693418

Surgical resection for recurrent hepatocellular carcinoma: prognosis and analysis of risk factors.

R H Hu1, P H Lee, S C Yu, H C Dai, J C Sheu, M Y Lai, H C Hsu, D S Chen.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is common in Asian countries, and tumor recurrence is the most common cause of treatment failure after curative resection. Repeated hepatectomy is performed only for selected patients because most patients with HCC also have liver cirrhosis and poor liver function reserve. The purposes of this study were to clarify the outcome of the patients after second hepatectomy for recurrent HCC and to evaluate the prognostic factors after second hepatectomy.
METHODS: We used retrospective cohort study to examine the disease-free survival, cumulative survival, and possible prognostic factors for recurrence and death in 59 patients who underwent surgical resection for recurrent HCC at the National Taiwan University Hospital from August 1986 to December 1993. Another 64 patients with unresectable recurrent HCC were used as a historical control group. The survival curves between those patients with resectable HCC and those with unresectable HCC were compared.
RESULTS: After resection for recurrent HCC, gender and multiplicity (n > 3) of tumor affect recurrence rate (p = 0.046 and 0.021, respectively), whereas gender, age, and tumor invasiveness affect survival rate significantly (p = 0.024, 0.021, and 0.046, respectively). The survival rate of patients with resectable HCC was significantly better than that of those with unresectable HCC.
CONCLUSIONS: For recurrent HCC surgical resection is an effective mode of treatment in selected patients. Whether surgery is better than other modes of treatment in the treatment of resectable recurrent HCC demands further investigation.

Entities:  

Mesh:

Year:  1996        PMID: 8693418     DOI: 10.1016/s0039-6060(96)80236-4

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  17 in total

1.  A prognostic model and treatment strategy for intrahepatic recurrence of hepatocellular carcinoma after curative resection.

Authors:  Yuzo Umeda; Hiroaki Matsuda; Hiroshi Sadamori; Hiroyoshi Matsukawa; Takahito Yagi; Toshiyoshi Fujiwara
Journal:  World J Surg       Date:  2011-01       Impact factor: 3.352

2.  Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma.

Authors:  Masami Minagawa; Masatoshi Makuuchi; Tadatoshi Takayama; Norihiro Kokudo
Journal:  Ann Surg       Date:  2003-11       Impact factor: 12.969

3.  Factors associated with disease survival after surgical resection in Chinese patients with hepatocellular carcinoma.

Authors:  Li Qiang; Li Huikai; Kelly Butt; P Peter Wang; Xishan Hao
Journal:  World J Surg       Date:  2006-03       Impact factor: 3.352

4.  4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) inhibits the intrahepatic spread of hepatocellular carcinoma and prolongs the life-span of tumor-bearing animals.

Authors:  K Murakami; T Matsuura; M Sano; A Hashimoto; K Yonekura; R Sakukawa; Y Yamada; I Saiki
Journal:  Clin Exp Metastasis       Date:  1998-10       Impact factor: 5.150

Review 5.  Effect of liver regeneration on malignant hepatic tumors.

Authors:  Ji-Hua Shi; Pål-Dag Line
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

6.  Nomogram predicting long-term survival after the diagnosis of intrahepatic recurrence of hepatocellular carcinoma following an initial liver resection.

Authors:  Tsuyoshi Notake; Akira Kobayashi; Hiroji Shinkawa; Takuya Kawahara; Akira Shimizu; Takahide Yokoyama; Kiyoshi Hasegawa; Norihiro Kokudo; Yutaka Matsuyama; Masatoshi Makuuchi; Shin-Ichi Miyagawa
Journal:  Int J Clin Oncol       Date:  2017-03-16       Impact factor: 3.402

7.  Involvement of hepatopoietin Cn in the development of human hepatocellular carcinoma.

Authors:  Bu-Dong Zhu; Xiao-Li Li; Yong Liu; Jing Chang; Yang Liu; Dong-Dong Zhang; Qiang Wang; Jun Ren; Chun-Ping Cui
Journal:  Clin Exp Metastasis       Date:  2010-08-04       Impact factor: 5.150

8.  Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCC.

Authors:  Zhong-Zhe Lin; Yung-Ming Jeng; Fu-Chang Hu; Hung-Wei Pan; Hsin-Wei Tsao; Po-Lin Lai; Po-Huang Lee; Ann-Lii Cheng; Hey-Chi Hsu
Journal:  BMC Cancer       Date:  2010-08-28       Impact factor: 4.430

9.  Total vascular exclusion technique for resection of hepatocellular carcinoma.

Authors:  Zhen-Yu Yin; Xiao-Ming Wang; Ren-Xiang Yu; Bai-Meng Zhang; Ke-Ke Yu; Ning Li; Jie-Shou Li
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

10.  Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation.

Authors:  Charles H Cha; Leyo Ruo; Yuman Fong; William R Jarnagin; Jinru Shia; Leslie H Blumgart; Ronald P DeMatteo
Journal:  Ann Surg       Date:  2003-09       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.